NCT04407377View on ClinicalTrials.gov

Effects of Tolperisone on Measures of Drowsiness and Cognitive Function

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 20, 2020

Primary Completion Date

October 16, 2020

Study Completion Date

March 31, 2021

Conditions
Healthy
Interventions
DRUG

Tolperisone Hydrochloride

Study Drug

DRUG

Cyclobenzaprine Hydrochloride 10 MG

Active Comparator

OTHER

Placebo

Placebo Comparator

Trial Locations (2)

90806

CNS Trial, Long Beach

08009

Hassman Research Institute, Berlin

Sponsors
All Listed Sponsors
lead

Neurana Pharmaceuticals, Inc.

INDUSTRY

NCT04407377 - Effects of Tolperisone on Measures of Drowsiness and Cognitive Function | Biotech Hunter | Biotech Hunter